FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W289557332> ?p ?o ?g. }

• W289557332 abstract "Surprise! I bet you thought Moody’s Investors Service rated only bonds and other arcane Wall Street instruments. In fact, Moody’s also evaluates specific sectors of our economy and renders its famous score on a host of individual pharmaceutical companies. I think you’ll find my quick review of Moody’s outlook on the U.S. drug industry to be of interest.1It should come as no shock to us that Moody’s says, “The outlook for the U.S. pharmaceutical industry is negative. This outlook expresses Moody’s expectations for the fundamental credit conditions in the industry over the next 12–18 months.”1What’s behind this gloomy point of view? I would like to explain the reasons and then discuss some future trends.Moody’s has actually maintained this opinion of our nation’s pharmaceutical sector since October 2007. Moody’s believes that the industry is now in a period of unprecedented uncertainty—the result of several factors, such as the expiration of patents in the next four years, hurdles facing the Food and Drug Administration (FDA), rising pressure from shareholders, merger and acquisition activity, and the potential for more radical shifts in the business model.I was surprised to learn that Moody’s gives individual ratings to individual global companies within the pharmaceutical sector. These ratings look a lot like the service’s famous bond ratings; in this case, they range from Aa to B3. For instance, Johnson & Johnson gets the highest rating (Aa), but Elan gets the lowest (B3). Remember, these ratings are only for major branded pharmaceutical companies throughout the world.I found it interesting that Moody’s went out of its way to cite formularies as a significant factor in the unfavorable ranking for the industry. The service cites the launch of several drugs that have performed below market expectations, in part because of formulary restrictions adopted by managed care organizations. I was ambivalent about this aspect of the report, in that I was pleased to see that formularies were indeed a part of the conversation but disappointed that Moody’s decided to cite the actions made in regard to the formularies as a negative component affecting this sector.Another surprise was Moody’s mention that although the current state of the industry is generally characterized by strong balance sheets and high levels of cash and investments relative to debt, much of this cash has accumulated in off-shore locations. Moody’s believes that this migration of cash to sites outside the U.S. is a detrimental phenomenon. In the past several years, cash needs in the U.S. (i.e., dividends, repurchases, acquisitions of U.S.-based companies) “have depleted U.S. cash levels while cash has accumulated off-shore.” Therefore, even though cash and investment holdings have grown, the amount considered to be based in the U.S. has rapidly decreased.What about the future?Moody’s envisions more mergers between large drug companies, possibly resulting in a potential significant upheaval. One reason is that similar molecules in the drug pipeline have been developed by multiple companies. Examples include dipeptidyl peptidase–IV (DPP-IV) inhibitors and glucagon-like peptide (GLP)–inhibitors for diabetes, factor X inhibitors for thrombosis, and cannabinoid receptor agonists for obesity. Given the significant research and development costs to achieve the FDA’s approval, followed by the substantial cost involved in marketing new products, Moody’s believes that these pipelines may prove a strong impetus for future mergers among current global giants.The final “Moody’s Musings,” which the service contends will be monitored closely, include areas such as the divestiture of nonpharmaceutical assets currently held by global companies, the ability of the industry to prepare for up-coming patent expirations, the effect of legislative changes, the way in which the companies deploy large amounts of offshore cash, and the extent to which the companies balance shareholder-friendly strategies with a desire to maintain high credit ratings.There is no question that the pharmaceutical industry is facing many challenges these days, and it is helpful to read experts’ evaluations whenever possible. I wouldn’t make a personal investment decision based on information solely from Moody’s, but its authors’ considerations are clearly important.As always, I am interested in your views. You can reach me at my e-mail address, ude.nosreffej@hsan.divad. I also hope you will visit my blog at http://departmentofhealthpolicy.blogspot.com." @default.
• W289557332 created "2016-06-24" @default.
• W289557332 creator A5050513604 @default.
• W289557332 date "2008-11-01" @default.
• W289557332 modified "2023-09-23" @default.
• W289557332 title "Moody's Musings." @default.
• W289557332 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2730810" @default.
• W289557332 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19750055" @default.
• W289557332 hasPublicationYear "2008" @default.
• W289557332 type Work @default.
• W289557332 sameAs 289557332 @default.
• W289557332 citedByCount "0" @default.
• W289557332 crossrefType "journal-article" @default.
• W289557332 hasAuthorship W289557332A5050513604 @default.
• W289557332 hasConcept C120757647 @default.
• W289557332 hasConcept C136264566 @default.
• W289557332 hasConcept C144024400 @default.
• W289557332 hasConcept C144133560 @default.
• W289557332 hasConcept C162324750 @default.
• W289557332 hasConcept C17744445 @default.
• W289557332 hasConcept C187736073 @default.
• W289557332 hasConcept C190253527 @default.
• W289557332 hasConcept C199539241 @default.
• W289557332 hasConcept C2779652045 @default.
• W289557332 hasConcept C2780343955 @default.
• W289557332 hasConcept C2780378061 @default.
• W289557332 hasConcept C39389867 @default.
• W289557332 hasConcept C46312422 @default.
• W289557332 hasConcept C71924100 @default.
• W289557332 hasConcept C98274493 @default.
• W289557332 hasConceptScore W289557332C120757647 @default.
• W289557332 hasConceptScore W289557332C136264566 @default.
• W289557332 hasConceptScore W289557332C144024400 @default.
• W289557332 hasConceptScore W289557332C144133560 @default.
• W289557332 hasConceptScore W289557332C162324750 @default.
• W289557332 hasConceptScore W289557332C17744445 @default.
• W289557332 hasConceptScore W289557332C187736073 @default.
• W289557332 hasConceptScore W289557332C190253527 @default.
• W289557332 hasConceptScore W289557332C199539241 @default.
• W289557332 hasConceptScore W289557332C2779652045 @default.
• W289557332 hasConceptScore W289557332C2780343955 @default.
• W289557332 hasConceptScore W289557332C2780378061 @default.
• W289557332 hasConceptScore W289557332C39389867 @default.
• W289557332 hasConceptScore W289557332C46312422 @default.
• W289557332 hasConceptScore W289557332C71924100 @default.
• W289557332 hasConceptScore W289557332C98274493 @default.
• W289557332 hasLocation W2895573321 @default.
• W289557332 hasOpenAccess W289557332 @default.
• W289557332 hasPrimaryLocation W2895573321 @default.
• W289557332 hasRelatedWork W1555211289 @default.
• W289557332 hasRelatedWork W1582837455 @default.
• W289557332 hasRelatedWork W1597800502 @default.
• W289557332 hasRelatedWork W191000027 @default.
• W289557332 hasRelatedWork W2099080670 @default.
• W289557332 hasRelatedWork W232381345 @default.
• W289557332 hasRelatedWork W281405917 @default.
• W289557332 hasRelatedWork W2917391571 @default.
• W289557332 hasRelatedWork W292178960 @default.
• W289557332 hasRelatedWork W3000539844 @default.
• W289557332 hasRelatedWork W31176076 @default.
• W289557332 hasRelatedWork W3124279276 @default.
• W289557332 hasRelatedWork W3125519210 @default.
• W289557332 hasRelatedWork W313580405 @default.
• W289557332 hasRelatedWork W314217980 @default.
• W289557332 hasRelatedWork W320492503 @default.
• W289557332 hasRelatedWork W5109341 @default.
• W289557332 hasRelatedWork W750576380 @default.
• W289557332 hasRelatedWork W789359430 @default.
• W289557332 hasRelatedWork W154319682 @default.
• W289557332 isParatext "false" @default.
• W289557332 isRetracted "false" @default.
• W289557332 magId "289557332" @default.
• W289557332 workType "article" @default.